Consideration of Audited Financial Results Standalone and Consolidated as per Indian Accounting Standards (Ind AS) along with the Audit Report of the Company for the Quarter and Year ended ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences reported audited standalone revenue of Rs. 11,223.10 Lacs for FY26 vs Rs. 294.28 Lacs in FY25 (massive increase), with PAT turning positive at Rs. 37.50 Lacs vs loss of Rs. 69.51 Lacs. However, Q4 standalone shows a loss of Rs. 26.61 Lacs. Consolidated revenue is Rs. 11,591.06 Lacs with PAT of Rs. 39.44 Lacs. Operating cash flow is significantly negative at Rs. 121.35 Lacs (standalone) and Rs. 257.92 Lacs (consolidated). The company also disclosed resignations of Non-Executive Director Mr. Hemant Parikh (effective March 17, 2026) and Company Secretary Ms. Chaitra Arora (effective April 30, 2026). All board committees have been reconstituted effective May 7, 2026. Auditors issued clean opinions with no qualifications or going concern doubts.
While FY26 shows a turnaround from losses to profitability with exceptional revenue growth, the strongly negative operating cash flows and high leverage (debt ~Rs. 1,019 Lacs vs equity ~Rs. 436 Lacs) raise concerns about financial sustainability. The Q4 loss and management departures may weigh on investor sentiment near-term.